

## Anti-C5a hlgG4 Antibody (vilobelimab)

### Product information


GM-88394AB-10	10 µg
GM-88394AB-100	100 µg
GM-88394AB-1000	1 mg

### Antibody Information

Species Reactivity	Human
Clone	Vilobelimab
Source/Isotype	Human IgG4(S228P), Kappa
Application	/
Target	Detects C5a
Gene	C5a
Other Names	C5a, Complement Component 5a
Gene ID	727 (Human)
Background	Vilobelimab is a monoclonal antibody that targets C5A, as a first-in-class recombinant chimeric IgG4 antibody, the central mechanism of which is through specific binding and blocking of the biological activity of complement factor C5A, which is the first-in-class recombinant chimeric IgG4 antibody, inhibition of neutrophil chemotaxis, degranulation, and burst of oxygen respiration, thereby controlling the inflammatory response while preserving the innate immune defense function of the membrane attack complex (C5b-9) , to avoid potential safety risks of conventional C5 inhibitors. As a pioneering drug targeting C5A, Vilobelimab has also shown therapeutic potential in neutrophil-mediated inflammatory diseases such as sepsis, acute respiratory distress syndrome (Ards) , ischemia-reperfusion injury, etc. , many countries in the world have launched phase III or Phase II clinical trials, and companies such as China are also deploying similar drug research and development, marking a breakthrough in the field of complement-targeted therapy in immunity and inflammation.
Storage	Store at 2-8°C short term (1-2 weeks).Store at ≤ -20°C long term. Avoid repeated freeze-thaw.
Formulation	Supplied as a 0.2 µm filtered solution of PBS, pH7.2-7.4.
Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay


Version:3.1

**SDS-PAGE**



On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

**SEC-HPLC**



The purity of this product is more than 90% verified by SEC-HPLC.